24.53

1.38% 0.2878

Catalyst Pharmaceuticals Inc (CPRX)

Overview News Price History Option Chain Financials Why CPRX Down? Discussions Forecast

Catalyst Pharmaceuticals Inc stock is traded at $24.53, with a volume of 250.60K. It is up +1.38% in the last 24 hours and up +0.51% over the past month. Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.

Previous Close:

$24.24

Open:

$24.1

24h Volume:

250.60K

Relative Volume:

0.21

Market Cap:

$2.99B

Revenue:

$460.48M

Net Income/Loss:

$142.80M

P/E Ratio:

20.79

EPS:

1.18

Net Cash Flow:

$221.79M

1W Performance:

+2.91%

1M Performance:

+0.51%

6M Performance:

+22.87%

1Y Performance:

+11.91%

1-Day Range:

$23.98

$24.66

1-Week Range:

$23.63

$24.94

52-Week Range:

$19.05

$26.58

Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile

Name

Catalyst Pharmaceuticals Inc

Sector

Healthcare (1111)

Industry

Biotechnology (618)

Phone

(305) 529-2522

Address

355 ALHAMBRA CIRCLE, CORAL GABLES

Employee

182

Twitter

@CatalystForRare

Next Earnings Date

2024-11-06

Latest SEC Filings

CPRX's Discussions on Twitter

Compare CPRX vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CPRX Catalyst Pharmaceuticals Inc	24.47	2.96B	460.48M	142.80M	221.79M	1.18
VRTX Vertex Pharmaceuticals Inc	453.93	116.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	771.38	80.33B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	726.37	44.42B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	316.44	42.53B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	299.69	33.32B	5.36B	287.73M	924.18M	2.5229

Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-04-25	Initiated	Robert W. Baird	Outperform
Nov-18-24	Initiated	Stephens	Overweight
Mar-14-24	Initiated	Citigroup	Buy
Mar-07-24	Initiated	BofA Securities	Buy
Dec-21-23	Initiated	Oppenheimer	Outperform
Aug-24-22	Downgrade	ROTH Capital	Buy → Neutral
Sep-21-18	Initiated	Cantor Fitzgerald	Overweight
Sep-07-18	Resumed	Piper Jaffray	Overweight
Oct-05-16	Upgrade	Piper Jaffray	Neutral → Overweight
Apr-26-16	Downgrade	Piper Jaffray	Overweight → Neutral
Sep-30-14	Reiterated	ROTH Capital	Buy
Sep-16-14	Reiterated	ROTH Capital	Buy
Sep-15-14	Reiterated	H.C. Wainwright	Buy
Oct-21-13	Reiterated	Aegis Capital	Buy
Sep-24-13	Initiated	Maxim Group	Buy
Sep-06-13	Reiterated	Aegis Capital	Buy
Apr-18-13	Initiated	Aegis Capital	Buy
Aug-27-12	Upgrade	Rodman & Renshaw	Mkt Perform → Mkt Outperform
Oct-01-09	Upgrade	Merriman	Sell → Neutral
May-29-09	Downgrade	Hapoalim	Neutral → Underperform
May-29-09	Downgrade	Merriman Curhan Ford	Buy → Sell
Dec-15-08	Initiated	Merriman Curhan Ford	Buy
Nov-28-07	Initiated	Rodman & Renshaw	Mkt Outperform
Jan-31-07	Initiated	Stifel Nicolaus	Buy
Jan-05-07	Initiated	First Albany	Buy

View All

Catalyst Pharmaceuticals Inc Stock (CPRX) Latest News

Mar 06, 2026

(CPRX) Movement as an Input in Quant Signal Sets - Stock Traders Daily

Mar 06, 2026

How Much Upside is Left in Catalyst (CPRX)? Wall Street Analysts Think 43.34% - Finviz

Mar 06, 2026

Real-world Duchenne data: how a novel steroid is used in care - Stock Titan

Mar 06, 2026

American Century Companies Inc. Purchases 770,198 Shares of Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat

Mar 06, 2026

Why Catalyst Pharmaceuticals (CPRX) Is Up 5.4% After Raising 2026 Revenue Guidance And Highlighting Rare Disease Portfolio - Yahoo Finance

Mar 06, 2026

Mar 05, 2026

Immunovant Stock Surges 17% in 3 Months: What's Driving It? - TradingView

Mar 05, 2026

AMRN Stock Soars 37.7% in a Year: Here's What You Need to Know - Finviz

Mar 05, 2026

Zacks Research Upgrades Catalyst Pharmaceuticals (NASDAQ:CPRX) to Strong-Buy - MarketBeat

Mar 05, 2026

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Strong Fundamental and Technical Setup - ChartMill

Mar 05, 2026